Hematology Frontier

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading investigators to discuss the latest advances in translational research, innovative therapies, and patient care.

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in research, innovative therapies, and patient care.

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma (MM), the congress brought together leading experts from around the world to discuss the latest advances in research, novel therapies, and patient care.

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in translational research, novel therapeutics, and patient care.

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma and related plasma cell disorders, the congress brought together leading experts worldwide to discuss the latest advances in translational research, novel therapeutics, and patient care.

From May 14–17, 2026, the 12th International Congress on Controversies in Multiple Myeloma (COMy 2026) was successfully held in Paris, France. Recognized as one of the most influential academic meetings in the field of multiple myeloma (MM), COMy has long been distinguished by its focused format, in-depth scientific discussions, and emphasis on unresolved clinical questions.

To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a professional event with high academic value, strong clinical relevance, and broad industry influence.

To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a professional event with high academic value, strong clinical relevance, and broad industry influence.

To further advance scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical diagnostic and treatment experience, and future directions in the discipline, creating a professional event of high academic caliber, strong clinical relevance, and significant industry influence.

To further advance both scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a high-level academic event with strong clinical and industry impact.